Moderna has withdrawn its application for a combination vaccine for flu and Covid-19 after discussions with the FDA and plans to resubmit later this year based on new efficacy data. This decision coincides with the FDA's requirements for new clinical trials for Covid booster approval for healthy individuals under 65. Moderna's stock has suffered due to declining Covid revenues and controversies surrounding the new Health Secretary. The timeline for a combination vaccine for adults over 50 has also shifted to 2026 as Moderna seeks to offset falling vaccine sales with new mRNA products.
Moderna's decision to withdraw its flu and Covid combination vaccine application follows FDA discussions, with expectations to resubmit later this year based on new trial data.
The company's shares have been affected by declining Covid revenue and concerns over the appointment of Robert F Kennedy Jr as Health Secretary.
Collection
[
|
...
]